Biogen Idec, Inc. (Massachusetts) Reports Four More Tysabri Cases, One Death

NEW YORK Dec 16 (Reuters) - Four more patients taking Biogen Idec's (BIIB.O) multiple sclerosis drug Tysabri have developed the serious brain infection known as PML and one of them died, according to the biotechnology company's monthly update.